CompoAtlas

COLLAGEN SUPERDOSE - SOUTIEN CHEVEUX

Food supplement declared in France, decision dated 28 January 2026

COLLAGEN SUPERDOSE - SOUTIEN CHEVEUX (MINERVA Research Labs) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
MINERVA Research Labs
Food business operator placing the product on the market
MINERVA RESEARCH LABS LIMITED
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Comprimé
Daily dose
1 comprimé par jour
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Peau, Cheveux et ongles

Declaration 353826, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Serenoa repens (W.Bartram) SmallFruitExtrait au CO2 supercritique50 mg
Piper nigrum L.FruitExtrait sec alcoolique0.5 mg

Other active ingredients

NamePer day
Glycinenot declared
Thréoninenot declared
Argininenot declared
L-Glutaminenot declared
Sérinenot declared
L-cystinenot declared
Collagène hydrolysénot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-biotineBiotine (vitamine B8)pas de limite (données insuffisantes)dose annulée par le Conseil d'État en 2011

Additives

E466, E470b, E551, E460

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas être utilisés comme substitut à une alimentation variée et équilibrée et à un mode de vie sain. Déconseillé aux femmes enceintes ou allaitante. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. Tenir hors de portée des jeunes enfants. Conserver dans un endroit frais et sec, à l'abri de la lumière directe du soleil et de la chaleur. Réservé aux adultes.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Serenoa repens (W.Bartram) Small
    Read the warning, when it applies and the studies cited

    SAW PALMETTO – SERENOA REPENS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Arginine
    Read the warning, when it applies and the studies cited

    L-ARGININE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Condition of application: Improvement in exercise capacity in individuals with stable CVD.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.

    Applies to products providing more than 0.42 g of L-Arginine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing more than 9 g of L-Arginine, per day.

    Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Applies to products providing more than 9 g of L-Arginine, per day.

    When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

  • L-Glutamine
    Read the warning, when it applies and the studies cited

    L-Glutamine

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 30 January 2026

  • Collagène hydrolysé
    Read the warning, when it applies and the studies cited

    Hydrolyzed Collagen

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Applies to products providing more than 2.8 g hydrolyzed collagen, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Shils et al. 2006; Goldman and Ausiello 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Moskowitz 2000).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : MINERVA Research Labs

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line